SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D – Medscape

by

  1. SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D Medscape
  2. Lilly’s SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes | Eli Lilly and Company Investors | Eli Lilly and Company
  3. ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin evaluate.com
  4. Step aside Ozempic and Wegovy — ‘landmark’ trial results for weight-loss drug Mounjaro just dropped, and they Business Insider India
  5. Lilly’s phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight | Eli Lilly and Investors | Eli Lilly and Company
  6. View Full Coverage on Google News

Read original article here

Leave a Comment